ACXP · Acurx Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| David P. Luci President and CEO | ▲ Buy | Open Market | 1,097,458 Shares held | 1/6/2025 | View profile |
| Robert J. Deluccia Director | ▲ Buy | Open Market | 1,010,196 Shares held | 1/6/2025 | View profile |
| Carl Sailer Director | ▲ Buy | Open Market | 137,183 Shares held | 1/6/2025 | View profile |
| Joseph C. Scodari Director | ▲ Buy | Open Market | 27,708 Shares held | 1/6/2025 | View profile |
| James J. Donohue Director | ▲ Buy | Open Market | 22,352 Shares held | 1/6/2025 | View profile |
| Jack H. Dean Director | ▲ Buy | Open Market | 21,776 Shares held | 1/6/2025 | View profile |
Transaction History
| Joseph C. Scodari | ▲ Buy | Open Market | 24,631 | $25K | 1/6/2025 |
| Carl Sailer | ▲ Buy | Open Market | 24,631 | $25K | 1/6/2025 |
| David P. Luci | ▲ Buy | Open Market | 49,261 | $50K | 1/6/2025 |
| James J. Donohue | ▲ Buy | Open Market | 9,852 | $10K | 1/6/2025 |
| Robert J. Deluccia | ▲ Buy | Open Market | 49,261 | $50K | 1/6/2025 |
| Jack H. Dean | ▲ Buy | Open Market | 9,852 | $10K | 1/6/2025 |
| Carl Sailer | ▲ Buy | Option Exercise | 19,737 | $70K | 1/19/2024 |
| Robert J. Deluccia | ▲ Buy | Option Exercise | 19,737 | $70K | 1/3/2024 |
| David P. Luci | ▲ Buy | Option Exercise | 19,737 | $70K | 1/3/2024 |
| Robert J. Deluccia | ▼ Sell | Gift | 30,000 | $0 | 12/22/2023 |
| Robert J. Deluccia | ▼ Sell | Gift | 40,000 | $0 | 12/12/2023 |
| Carl Sailer | ▲ Buy | Open Market | 19,737 | $75K | 7/27/2022 |
| Robert J. Deluccia | ▲ Buy | Open Market | 19,737 | $75K | 7/27/2022 |
| David P. Luci | ▲ Buy | Open Market | 19,737 | $75K | 7/27/2022 |
| Robert J. Deluccia | ▼ Sell | Gift | 40,000 | $0 | 12/2/2021 |
| Carl Sailer | ▲ Buy | Open Market | 5,161 | $25K | 11/23/2021 |
| Robert J. Deluccia | ▲ Buy | Open Market | 5,034 | $25K | 11/19/2021 |
| David P. Luci | ▲ Buy | Open Market | 5,200 | $25K | 11/19/2021 |
| Carl Sailer | ▲ Buy | Open Market | 12,500 | $75K | 6/29/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial
Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial. Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.